Company news

Xeris Biopharma Holdings, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Xeris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Corporate Highlights

August 9, 2020

Xeris Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020

August 2, 2020

Xeris Pharmaceuticals Announces Additional Data From a Phase 1b Comparative Study of Its Novel Concentrated Diazepam Formulation (XP-0863) and an Expedited Clinical Path Forward

July 29, 2020

Xeris Pharmaceuticals Announces Full Exercise of Underwriters’ Options to Purchase Additional Shares and Additional Notes

July 14, 2020

Xeris Pharmaceuticals Announces Gvoke HypoPen™ – the First Autoinjector for Severe Hypoglycemia – Now Available

June 30, 2020

Xeris Pharmaceuticals Announces Pricing of Public Offerings of $20 Million of Common Stock and $75 Million of 5.00% Convertible Senior Notes Due 2025

June 24, 2020

Xeris Pharmaceuticals Announces Proposed Public Offerings of $20 Million of Common Stock and $60 Million of Convertible Senior Notes

June 23, 2020

Xeris Pharmaceuticals Announces Positive Topline Results from the Phase 2 Comparative Study of a Novel Pramlintide-insulin Co-formulation (XP-3924) in Adults with Type 1 Diabetes Mellitus

June 17, 2020

Xeris Pharmaceuticals Announces Positive Results From the Outpatient Stage of a Phase 2 Study of Its Developmental Gvoke Ready-to-Use (RTU) Micro™ Glucagon in Adults at Risk of Hypoglycemia During and After Aerobic Exercise

June 14, 2020

Xeris Pharmaceuticals Announces Positive Findings From the Outpatient Portion of a Phase 2 Proof-of-Concept Study of Its Developmental Ready-to-Use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery

May 21, 2020

Xeris Pharmaceuticals Signs Exclusive Agreement With Clinigen to Supply and Distribute Gvoke™ Outside the U.S on a Named Patient Basis

May 13, 2020

Xeris Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Updates

May 6, 2020

Xeris Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020

April 29, 2020

Xeris Extends $0 Copay for Gvoke™ PFS For People With Diabetes Through May 31, 2020

April 28, 2020

Xeris Pharmaceuticals Announces Positive Topline Results From a Study of Its Novel Formulation of Diazepam Injection

April 19, 2020

Xeris Pharmaceuticals Announces $0 Copay for Gvoke™ PFS for People With Diabetes

March 25, 2020

Xeris Pharmaceuticals Reinforces the Importance of GVOKE™ PFS for People With Diabetes

March 18, 2020

Xeris Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Pipeline Progress

March 10, 2020

Xeris Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 11, 2020

February 26, 2020

Xeris Pharmaceuticals Announces Exercise of Underwriters’ Option to Purchase Additional Shares

February 19, 2020

Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference

February 17, 2020

Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock

February 10, 2020

Xeris Pharmaceuticals Announces Proposed Public Offering of 6,000,000 Shares of Common Stock

February 9, 2020

Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of Hypoglycemia During and after Aerobic Exercise

January 5, 2020

Xeris Pharmaceuticals Announces Positive Topline Results From the In-clinic Stage of the Phase 2 Study of Its Developmental Ready-to-use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery

December 9, 2019

Xeris Pharmaceuticals Provides a Business Update During Recent Investor Conference

November 20, 2019

Xeris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights

November 6, 2019

Xeris Pharmaceuticals Appoints Mark Thierer to Board of Directors

September 30, 2019

Xeris Pharmaceuticals Begins Dosing Patients in a Phase 2 Clinical Trial Evaluating Its Novel Fixed-Ratio Co-Formulation of Pramlintide-Insulin for Diabetes

September 18, 2019

Xeris Pharmaceuticals Announces Expanded $85 Million Debt Facility With Oxford Finance and Silicon Valley Bank

September 9, 2019

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

August 29, 2019

← Newer news releases

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks